Get the Stockscreener App
1.665
9.54%
0.145
Precigen Inc stock is traded at $1.665, with a volume of 633.78K.
It is up +9.54% in the last 24 hours and up +12.50% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$1.52
Open:
$1.59
24h Volume:
633.78K
Relative Volume:
0.33
Market Cap:
$492.95M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-4.2692
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
-9.51%
1M Performance:
+12.50%
6M Performance:
+24.25%
1Y Performance:
+0.91%
1-Day Range:
$1.54
$1.70
1-Week Range:
$1.47
$1.92
52-Week Range:
$0.6513
$2.17
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
1.67 | 546.08M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.48 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.50 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.06 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.01 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.35 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Is Precigen Inc. a good long term investmentFree Capital Allocation Plans - jammulinksnews.com
What drives Precigen Inc. stock priceSky-high profits - Autocar Professional
What analysts say about Precigen Inc. stockConsistent double returns - Autocar Professional
Precigen Inc. Stock Analysis and ForecastBreakout stock performance - jammulinksnews.com
Why Did Precigen Plunge 11.48%? - AInvest
Private Equity Firms Who Have a Significant Stake Must Be Disappointed Along With Institutions After Precigen, Inc.'s (NASDAQ:PGEN) Market Cap Dropped by US$56m - 富途牛牛
HC Wainwright Predicts Precigen’s Q1 Earnings (NASDAQ:PGEN) - Defense World
What makes Precigen Inc. stock price move sharplyDaily Price Surge List - Newser
Why Precigen Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser
How Precigen Inc. stock performs during market volatilityMoney Making Low Risk Plans - Newser
Precigen (NASDAQ:PGEN) Upgraded at Wall Street Zen - Defense World
Precigen shares rise 7.37% in premarket after FDA sets priority review date for PRGN-2012. - AInvest
Precigen shares rise 2.11% in after-hours after FDA sets priority review date for PRGN-2012. - AInvest
Precigen Inc (NASDAQ: PGEN) Up 15.99% This Year: What To Expect Next - Stocksregister
Precigen's PRGN-2012: A Rare Disease Breakthrough Awaits FDA Decision in August 2025 - AInvest
Precigen: August Is Pivotal For This Biotech Innovator - Seeking Alpha
Precigen Announces Key Approvals at Annual Meeting - The Globe and Mail
Precigen chief commercial officer: How AI is impacting rare disease marketing - Medical Marketing and Media
Closing Strong: Precigen Inc (PGEN) Ends at 1.42, Down -7.79 from Last Close - DWinneX
High Growth Tech Stocks To Watch In The US June 2025 - simplywall.st
Bank of America Corp DE Has $232,000 Position in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen stock price target maintained at $6 by JMP on RRP therapy - Investing.com Nigeria
Precigen’s SWOT analysis: gene therapy firm’s stock poised for potential breakthrough - Investing.com Australia
Precigen (NASDAQ:PGEN) Given “Market Outperform” Rating at JMP Securities - Defense World
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precigen Inc Stock (PGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Perez Jeffrey Thomas | SVP, IP Affairs |
Aug 09 '24 |
Buy |
0.85 |
58,823 |
50,000 |
743,097 |
| KIRK RANDAL J | Director |
Aug 09 '24 |
Buy |
0.85 |
23,529,411 |
19,999,999 |
64,547,214 |
4.79%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):